Every 424B that Nektar Therapeutics (NKTR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NKTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTR filings page.
Nektar Therapeutics filed a prospectus supplement to offer up to $150,000,000 of common stock through an Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC, enabling at-the-market sales from time to time. The sales agents will be paid a 3.0% commission and settlement is generally one business day after each sale.
The prospectus states an illustrative sale of 1,762,839 shares at an assumed price of $85.09 (last reported sale price on May 6, 2026), and discloses 33,786,032 shares outstanding as of April 30, 2026. Net proceeds are for general corporate purposes, including R&D and clinical development (notably Phase 3 trials for rezpegaldesleukin).
Nektar Therapeutics is offering 3,532,609 shares of its common stock pursuant to a prospectus supplement, at a public offering price of $92.00 per share. The offering is expected to yield approximately $305.1 million in net proceeds before expenses (about $350.9 million if the underwriters exercise their full 30-day option for 529,891 additional shares). Shares outstanding used for this offering are stated as 29,679,647 shares as of April 1, 2026. The company intends to use proceeds for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs to advance its drug candidates.
Nektar Therapeutics is offering $250,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable for common stock, pursuant to a preliminary prospectus supplement dated April 20, 2026. The offering is part of a shelf registration and is subject to completion; proceeds are intended for general corporate purposes including research, clinical development and manufacturing for rezpegaldesleukin and other programs.
The company reported preliminary cash and marketable securities of approximately $741.7 million as of April 1, 2026 and completed an at-the-market program that raised about $110.0 million from 1,532,850 shares sold at a weighted average price of $71.76. Outstanding common shares used for offering calculations are 29,679,647 as of April 1, 2026.
Nektar Therapeutics is offering 6,603,449 shares of common stock and pre-funded warrants to purchase up to 293,103 shares, at $58.00 per share (or $57.9999 per pre-funded warrant), for estimated net proceeds of about $375.6 million, or $432.0 million if the underwriters fully exercise their option for 1,034,482 additional shares.
The company plans to use the cash, together with existing funds, for general corporate purposes, including research, clinical development and manufacturing, notably Phase 3 trials for its autoimmune drug candidate rezpegaldesleukin. Nektar reported preliminary cash and marketable securities of approximately $229.1 million as of January 31, 2026.
Recent Phase 2b REZOLVE‑AD data in atopic dermatitis showed sustained efficacy through 52 weeks and a well‑tolerated safety profile, and Nektar has aligned with the FDA on two Phase 3 registrational trials starting in the second quarter of 2026. The company highlights significant dilution to new investors versus its September 30, 2025 net tangible book value per share.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics launched an at-the-market offering to sell up to $110,000,000 of common stock under an Equity Distribution Agreement with Piper Sandler & Co. and BTIG, LLC. Sales may occur from time to time as “at the market offerings” under Rule 415, and the agents will use commercially reasonable efforts. The program is part of Nektar’s existing $300,000,000 shelf registration. The sales agents are deemed underwriters and will receive a 3.0% commission on gross sales.
Nektar plans to use net proceeds for general corporate purposes, including research and clinical development of rezpegaldesleukin, NKTR‑0165, and NKTR‑255, plus working capital and potential investments. Nektar’s common stock trades on Nasdaq as NKTR; the last reported sale price was $57.97 per share on November 10, 2025. Shares outstanding were 19,652,513 as of September 30, 2025.